How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
53
CHGCF Quote, Financials, Valuation and Earnings
Last price:
$57.95
Seasonality move
:
10.47%
Day range:
$55.85 - $57.95
52-week range:
$38.76 - $72.30
Dividend yield:
1.48%
P/E ratio:
30.76x
P/S ratio:
10.60x
P/B ratio:
6.90x
Volume:
756
Avg. volume:
1.7K
1-year change:
18.23%
Market cap:
$89.1B
Revenue:
$8.4B
EPS (TTM):
$1.76
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Chugai Pharmaceutical Co., Ltd. has -- downside to fair value with a price target of -- per share.
CHGCF vs. S&P 500
-
Over the past 5 trading days, Chugai Pharmaceutical Co., Ltd. has underperformed the S&P 500 by -6.8% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Chugai Pharmaceutical Co., Ltd. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Chugai Pharmaceutical Co., Ltd. has grown year-over-year revenues for 2 quarters straight. In the most recent quarter Chugai Pharmaceutical Co., Ltd. reported revenues of $2.2B.
Earnings Growth
-
Chugai Pharmaceutical Co., Ltd. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Chugai Pharmaceutical Co., Ltd. reported earnings per share of $0.51.
Enterprise value:
82.9B
EV / Invested capital:
6.41x
Price / LTM sales:
10.60x
EV / EBIT:
19.75x
EV / Revenue:
9.86x
PEG ratio (5yr expected):
2.28x
EV / Free cash flow:
45.96x
Price / Operating cash flow:
42.02x
Enterprise value / EBITDA:
19.82x
Gross Profit (TTM):
$6B
Return On Assets:
19.41%
Net Income Margin (TTM):
34.47%
Return On Equity:
22.53%
Return On Invested Capital:
22.41%
Operating Margin:
48.92%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $7.9B | $7.7B | $8.4B | $2B | $2.2B | |
| Gross Profit | $5B | $5.5B | $6B | $1.4B | $1.7B | |
| Operating Income | $3B | $3.6B | $4.2B | $808M | $1.1B | |
| EBITDA | $3B | $3.7B | -- | $892.7M | -- | |
| Diluted EPS | $1.41 | $1.55 | $1.76 | $0.37 | $0.51 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.2B | $10.1B | $9.7B | $10.2B | $11.1B | |
| Total Assets | $13.4B | $14.2B | $13.7B | $14.1B | $15.7B | |
| Current Liabilities | $2.8B | $3.2B | $2B | $1.8B | $2.6B | |
| Total Liabilities | $3B | $3.4B | $2.2B | $2B | $2.8B | |
| Total Equity | $10.3B | $10.8B | $11.5B | $12.1B | $12.9B | |
| Total Debt | $139.3M | $106.9M | $95.4M | $69.3M | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $3B | $2.9B | $2.5B | $962.2M | $768.2M | |
| Cash From Investing | -$295M | -$1.5B | -$1.3B | -$85.4M | -$1B | |
| Cash From Financing | -$1B | -$926.3M | -$2B | $6.5M | $75.6M | |
| Free Cash Flow | $2.4B | $2.6B | $1.8B | $960.3M | $560.8M | |
CHGCF
Sector
Market Cap
$89.1B
$23.7M
Price % of 52-Week High
74.91%
49.4%
Dividend Yield
1.48%
0%
Shareholder Yield
3.28%
-1.67%
1-Year Price Total Return
18.23%
-20.73%
Beta (5-Year)
-0.091
0.502
Dividend yield:
1.48%
Annualized payout:
$1.79
Payout ratio:
188.41%
Growth streak:
2 years
Technicals
8-day SMA
Buy
Level
$56.87
200-day SMA
Buy
Level
$50.31
Bollinger Bands (100)
Buy
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$54.65
Relative Strength Index (RSI14)
Buy
Level
55.97
ADX Line
Neutral
Level
0
Williams %R
Neutral
Level
-55.1308
50-day SMA
Buy
Level
$54.17
MACD (12, 26)
Buy
Level
12.59
25-day Aroon Oscillator
Buy
Level
36
On Balance Volume
Neutral
Level
--
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (22.2692)
Buy
CA Score
(Annual)
Level (2.5093)
Buy
Beneish M-Score
(Annual)
Level (-2.7233)
--
Momentum Score
Level (--)
Buy
Ohlson Score
Level (-6.4069)
Buy
Piotroski F Score
(Annual)
Level (7)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.
Stock Forecast FAQ
In the current month, CHGCF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CHGCF average analyst price target in the past 3 months is --.
-
Where Will Chugai Pharmaceutical Co., Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Chugai Pharmaceutical Co., Ltd. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Chugai Pharmaceutical Co., Ltd.?
Analysts are divided on their view about Chugai Pharmaceutical Co., Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Chugai Pharmaceutical Co., Ltd. is a Sell and believe this share price will rise from its current level to --.
-
What Is Chugai Pharmaceutical Co., Ltd.'s Price Target?
The price target for Chugai Pharmaceutical Co., Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CHGCF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Chugai Pharmaceutical Co., Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of CHGCF?
You can purchase shares of Chugai Pharmaceutical Co., Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Chugai Pharmaceutical Co., Ltd. shares.
-
What Is The Chugai Pharmaceutical Co., Ltd. Share Price Today?
Chugai Pharmaceutical Co., Ltd. was last trading at $57.95 per share. This represents the most recent stock quote for Chugai Pharmaceutical Co., Ltd.. Yesterday, Chugai Pharmaceutical Co., Ltd. closed at $54.16 per share.
-
How To Buy Chugai Pharmaceutical Co., Ltd. Stock Online?
In order to purchase Chugai Pharmaceutical Co., Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get CHGCF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CHGCF
Sector
P/E ratio
30.76x
23.26x
PEG ratio
2.28x
-0.01x
P/B ratio
6.90x
1.77x
Price / LTM sales
10.60x
1.54x
Growth Metrics
CHGCF
Sector
Revenue growth
13.38%
3.94%
Earnings growth
38.7%
9.72%
Revenue (5-year growth)
2.67%
6.15%
Earnings forecast
--
-$0.19
Profitability
CHGCF
Sector
Profitability FY 2025
$6B
$2.7M
Return on invested capital
22.41%
-33.43%
Return on assets
19.41%
-29.68%
Return on equity
22.53%
-38.98%
Earnings Date
Last Earnings Date
Jan
29
Next Earnings Date
Apr
24
Estimated Next Earnings Date
Apr
30
Balance Sheet
CHGCF
Sector
Total cash
$6.3B
$25M
Short term investments
$2.9B
$23.9M
Total assets
$15.7B
$71.9M
Long term debt
--
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
34
ENPH alert for Feb 4
Enphase Energy, Inc. [ENPH] is up 38.57% over the past day.
Sell
13
CRVL alert for Feb 4
CorVel Corp. [CRVL] is down 5.54% over the past day.
Sell
26
IT alert for Feb 4
Gartner, Inc. [IT] is down 1.24% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
